Research Article
Effect of Artemisinin Based Combination Therapies Treatment on Antibodies Production in Children and Adults with Uncomplicated Malaria in Malaria Hyper-Endemic Area of Burkina Faso
Fatimata Thiombiano, Aboubacar
Coulibaly, San Maurice Ouattara,
Guillaume Sylvestre Sanou, Moise
Kabore, Amidou Diarra, Yves Traore,
Issiaka Soulama, Sodiomon Bienvenu
Sirima, Issa Nebie
Correspondence Address :
Issa Nebie
Centre National
de Recherche et de Formation sur le Paludisme
4Groupe de Recherche Action en Sante (GRAS)
Ouagadougou
Burkina Faso
West Africa
Tel: +226
70784195
Email: issanebie.cnlp@fasonet.bf
Received on: February 19, 2018, Accepted on: March 09, 2018, Published on: March 15, 2018
Citation: Issa Nebie, Fatimata Thiombiano, Aboubacar Coulibaly, et al. (2018). Effect of Artemisinin Based Combination Therapies Treatment on
Antibodies Production in Children and Adults with Uncomplicated Malaria in Malaria Hyper-Endemic Area of Burkina Faso
Copyright: 2018 Issa Nebie, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background: Artemisinin-based Combination Therapies (ACTs) are the first line drug for the treatment of uncomplicated malaria in most malaria endemic countries. They quickly clear the parasitaemia and reduce fever. In animal models it has been found that artemisinin derivatives have an immunosuppressive effect. In the present study we assessed the effect of ACTs on malaria antigens specific antibodies production in a population living in malaria hyperendemic area.
Methods: In 2012, 102 patients aged over 6 months and adults, presenting uncomplicated malaria were recruited and allocated to receive ACTs and follow up to 2 years. Antibodies titers against three P.falciparum blood stage malaria vaccine candidates (MSP3, GLURP R0, and GLURP R2) were measured by ELISA before treatment and 28 days (D28) after treatment with ACTs.
Results: Antibody levels were always higher 28 days after the initiation of the treatment for all tested antigens but not statiscally significant. An increase in antibody responses to MSP3 and R0 from D0 to D28 was also observed in children below 5 years of age with a borderline statistical significance.
Conclusion: The ACTs were effective on parasite clearance. Rapid clearance of parasitaemia was associated with age and did not prevent antibodies production. No immuno-suppressive action was observed in our study population.